Adoptive cell therapy for Melanoma using tumour infiltrating lymphocytes: John Bridgeman
22 Tampilan
administrator
07/30/23
A look at the use of TIL in Melanoma and future TIL engineering strategies. John Bridgeman is the Director of Cell Therapy Research at Immetacyte Ltd
Menampilkan lebih banyak
Komentar Facebook
Tidak ada komentar yang ditemukan